Psychiatric Services in the Era of Cannabis Policy Reform in Thailand, 1979–2026
Abstract
Background: Cannabis in Thailand has been reformed several times, ranging from strictly prohibiting the use of cannabis to widespread decriminalization in 2022, and it was subsequently returned to medical use proposes later. The authors intended to highlight how the transition of cannabis policy affects psychiatric services, clinical practice, and patient outcomes in Thailand. Methods: The authors did a scoping review to collect information from the relevant literature published between 1979 and 2026. The databases included PubMed, Scopus, ThaiJO, and gray literature. The data were grouped into topics, including policy eras, impacts on clinical outcomes, clinical guidelines, and pharmacological considerations. Results: After the shift from cannabis medicalization to decriminalization and then reregulation, Thailand addressed numerous consequences. The increased accessibility of cannabis was related to the usage behavior. As a result, the prevalence of cannabis-related disorders and hospitalization associated with cannabis use was rising, especially in minors. A guideline on cannabis for medical use pointed out that cannabis products are not recommended as the first-line treatment for physical conditions such as chemotherapy-induced nausea and central neuropathic pain. Many Thai patients were taking medications for their underlying medical conditions and were exposed to cannabis products; hence, possible drug–drug interactions through the cytochrome P450 system should be considered. Conclusion: Currently, cannabis legalization has a significant impact on health, social, and economic dimensions, causing a gap between patients’ health services and the legal framework. Patients and their guardians should be informed of the potential risks, benefits, and limitations of cannabis use, as well as interactions of cannabis–psychotropic drugs and long-term impacts.
Related
- Prenatal cannabis use disorder and postpartum psychiatric emergency department visits: A retrospective cohort study of trends and associations in California, 2016–2021
- Real-world effectiveness of psychiatric pharmacotherapies in reducing the risk of substance use- and psychiatric hospitalisations in cannabis use disorder – An exploratory nationwide register-based study
- Agenda-setting for pharmaceutical subsidy reform in Iran: a qualitative multiple streams analysis of the Darooyar policy
- Protecting public health in mining: a Q-methodology examination of policy space and reform pathways in Tanzania.
- Variation in public health reimbursement policies of ECT and rTMS across 28 European countries: A call for evidence-based policy reform from the ECNP Neuromodulation Network
BibTeX
@article{kamonpornwannarit2026psychiatric,
title = {{Psychiatric Services in the Era of Cannabis Policy Reform in Thailand, 1979–2026}},
author = {Kamonporn Wannarit, M.D. and Woraphat Ratta-Apha, M.D., Ph.D. and Pichet Udomratn, M.D.},
journal = {Taiwanese Journal of Psychiatry},
year = {2026},
month = jul,
doi = {10.4103/tpsy.tpsy_24_26},
url = {https://doi.org/10.4103/tpsy.tpsy_24_26},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Psychiatric Services in the Era of Cannabis Policy Reform in Thailand, 1979–2026
AU - Kamonporn Wannarit, M.D.
AU - Woraphat Ratta-Apha, M.D., Ph.D.
AU - Pichet Udomratn, M.D.
PY - 2026
DA - 2026/07/01
JO - Taiwanese Journal of Psychiatry
DO - 10.4103/tpsy.tpsy_24_26
UR - https://doi.org/10.4103/tpsy.tpsy_24_26
AB - Background: Cannabis in Thailand has been reformed several times, ranging from strictly prohibiting the use of cannabis to widespread decriminalization in 2022, and it was subsequently returned to medical use proposes later. The authors intended to highlight how the transition of cannabis policy affects psychiatric services, clinical practice, and patient outcomes in Thailand. Methods: The authors did a scoping review to collect information from the relevant literature published between 1979 and 2026. The databases included PubMed, Scopus, ThaiJO, and gray literature. The data were grouped into topics, including policy eras, impacts on clinical outcomes, clinical guidelines, and pharmacological considerations. Results: After the shift from cannabis medicalization to decriminalization and then reregulation, Thailand addressed numerous consequences. The increased accessibility of cannabis was related to the usage behavior. As a result, the prevalence of cannabis-related disorders and hospitalization associated with cannabis use was rising, especially in minors. A guideline on cannabis for medical use pointed out that cannabis products are not recommended as the first-line treatment for physical conditions such as chemotherapy-induced nausea and central neuropathic pain. Many Thai patients were taking medications for their underlying medical conditions and were exposed to cannabis products; hence, possible drug–drug interactions through the cytochrome P450 system should be considered. Conclusion: Currently, cannabis legalization has a significant impact on health, social, and economic dimensions, causing a gap between patients’ health services and the legal framework. Patients and their guardians should be informed of the potential risks, benefits, and limitations of cannabis use, as well as interactions of cannabis–psychotropic drugs and long-term impacts.
SN - 1028-3684
SN - 2666-2078
ER -